Pravachol Exclusivity Ruling Adds Uncertainty For ANDA Filers, Counsel Says
Executive Summary
A court decision reinstating Teva's generic exclusivity rights for Pravachol will make it more difficult for ANDA filers to predict when a dismissed declaratory judgment action could trigger 180-day exclusivity, FDA Associate Chief Counsel Elizabeth Dickinson said Oct. 26
You may also be interested in...
Pravachol Exclusivity: Teva Wins By Winning– FDA Wins By Losing?
A recent D.C. federal appeals court decision affirming Teva's exclusivity period for Pravachol generics opens the door for new standard-setting by FDA on what conditions trigger the start of 180-day exclusivity
Pravachol Exclusivity: Teva Wins By Winning– FDA Wins By Losing?
A recent D.C. federal appeals court decision affirming Teva's exclusivity period for Pravachol generics opens the door for new standard-setting by FDA on what conditions trigger the start of 180-day exclusivity
Zocor Exclusivity: Ranbaxy Needs Quick Win In Suit Seeking Patent Re-Listing
Ranbaxy needs a relatively quick win in its lawsuit against FDA if it hopes to benefit from the 180-day exclusivity it is claiming for Zocor 80 mg